Article

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Department of Pediatrics, Baylor Cancer Genetics Clinic, Baylor College of Medicine, Houston, Texas, USA.
Human Mutation (Impact Factor: 5.05). 11/2008; 29(11):1282-91. DOI: 10.1002/humu.20880
Source: PubMed

ABSTRACT Genetic testing of cancer susceptibility genes is now widely applied in clinical practice to predict risk of developing cancer. In general, sequence-based testing of germline DNA is used to determine whether an individual carries a change that is clearly likely to disrupt normal gene function. Genetic testing may detect changes that are clearly pathogenic, clearly neutral, or variants of unclear clinical significance. Such variants present a considerable challenge to the diagnostic laboratory and the receiving clinician in terms of interpretation and clear presentation of the implications of the result to the patient. There does not appear to be a consistent approach to interpreting and reporting the clinical significance of variants either among genes or among laboratories. The potential for confusion among clinicians and patients is considerable and misinterpretation may lead to inappropriate clinical consequences. In this article we review the current state of sequence-based genetic testing, describe other standardized reporting systems used in oncology, and propose a standardized classification system for application to sequence-based results for cancer predisposition genes. We suggest a system of five classes of variants based on the degree of likelihood of pathogenicity. Each class is associated with specific recommendations for clinical management of at-risk relatives that will depend on the syndrome. We propose that panels of experts on each cancer predisposition syndrome facilitate the classification scheme and designate appropriate surveillance and cancer management guidelines. The international adoption of a standardized reporting system should improve the clinical utility of sequence-based genetic tests to predict cancer risk.

0 Bookmarks
 · 
196 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genetic sequencing has become a critical part of the diagnosis of certain forms of pancreatic beta cell dysfunction. Despite great advances in the speed and cost of DNA sequencing, determining the pathogenicity of variants remains a challenge, and requires sharing of sequence and phenotypic data between laboratories. We reviewed all diabetes and hyperinsulinism-associated molecular testing done at the Seattle Children’s Molecular Genetics Laboratory from 2009-2013. 331 probands were referred to us for molecular genetic sequencing for Neonatal Diabetes (NDM), Maturity-Onset Diabetes of the Young (MODY), or Congenital Hyperinsulinism (CHI) during this period. Reportable variants were identified in 115 (35%) patients with 91 variants in one of 6 genes: HNF1A, GCK, HNF4A, ABCC8, KCNJ11, or INS. In addition to identifying 23 novel variants, we identified unusual mechanisms of inheritance, including mosaic and digenic MODY presentations. Re-analysis of all reported variants using more recently available databases led to a change in variant interpretation from the original report in 30% of cases. These results represent a resource for molecular testing of monogenic forms of diabetes and hyperinsulinism, providing a mutation spectrum for these disorders in a large North American cohort. In addition, they highlight the importance of periodic review of molecular testing results.
    Molecular Genetics and Metabolism 12/2014; · 2.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hereditary Diffuse Gastric Cancer is an autosomal dominant inherited gastric cancer syndrome caused by germline alterations in CDH1 (E-cadherin) and CTNNA1 (alpha-E-catenin) genes. Germline CDH1 alterations encompass small frameshifts, splice-site, nonsense, and missense mutations, as well as large rearrangements. Most CDH1 truncating mutations are pathogenic, and several missense CDH1 mutations have a deleterious effect on E-cadherin function. CDH1 testing should be performed in probands. Screening of at-risk individuals is indicated from the age of consent following counselling with a multidisciplinary team. In mutation-positive individuals prophylactic gastrectomy is recommended. Endoscopic surveillance is an option for those refusing/postponing gastrectomy, those with mutations of undetermined significance, and in CDH1-negative families. Ongoing research focus on the search of genetic causes other than CDH1 or CTNNA1 germline defects; assessment of the pathogenicity and penetrance of CDH1 missense mutations and identification of somatic mechanisms behind the progression from early (indolent) lesions to invasive (lethal) carcinomas.
    Baillière&#x027 s Best Practice and Research in Clinical Gastroenterology 12/2014; · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die massive parallele Sequenzierung (MPS) findet in der molekulargenetischen Diagnostik erblicher Krebserkrankungen zunehmend Einsatz, hier insbesondere bei Verdacht auf erblichen Brust- und Eierstockkrebs. Die potenziellen Vorteile von MPS im Vergleich zu bisher verwendeten (z. B. Sanger-sequenzbasierten) Methoden sind ein höherer Probendurchsatz, kürzere Bearbeitungszeiten und verminderte Kosten. Der Einsatz in der Routinediagnostik wird durch die Verfügbarkeit von zertifizierten Kits für die Probenvorbereitung vereinfacht. Hier wird die Validierung von 2 verschiedenen MPS-Geräten für die BRCA1-/-2-Diagnostik beschrieben. Bei Verwendung der Technik müssen die jeweiligen Vor- und Nachteile der einzelnen Geräte bedacht werden. Die Ergebnisse der MPS-Sequenzierung entsprechen denen, die mit Sanger-Sequenzierung ermittelt wurden. Abstract During the past few years, application of massively-parallel sequencing (MPS) in molecular diagnostics of hereditary cancer has increased significantly. The potential advantages of MPS, compared for example to Sanger sequencing-based methods, are higher sample capacities, shorter turnaround times, and decreased costs. Adoption in routine diagnostics is simplified due to the availability of certified kits for sample preparation. Here, the validation of two MPS systems for routine BRCA1/2 sequencing diagnostics are describe. Users should keep in mind the technical advantages and disadvantages of the individual sequencing machines. The results achieved with MPS are equal to those from Sanger sequencing.
    Medizinische Genetik 06/2014; 26(2):255-263. · 0.09 Impact Factor

Full-text (2 Sources)

Download
72 Downloads
Available from
Jun 6, 2014